Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition

• Published in: Scientific reports 2023-01, Vol.13 (1), p.1273-1273, Article 1273
• Main Authors: Graziani, Vittoria, Garcia, Aida Rodriguez, Alcolado, Lourdes Sainero, Le Guennec, Adrien, Henriksson, Marie Arsenian, Conte, Maria R.
• Format: Article
• Language: English
• Subjects: 631/57; 631/67; 631/80; 692/308; 692/4028; 692/699; Ascorbic acid; Biosynthesis; Brain tumors; Cell Line, Tumor; Cerebellar Neoplasms - pathology; Child; Children; Humanities and Social Sciences; Humans; Inositol phosphate; Lipid metabolism; Medicin och hälsovetenskap; Medulloblastoma; Medulloblastoma - pathology; Metabolism; Metabolomics; multidisciplinary; Myc protein; N-Acetylglucosamine; Nuclear Proteins - metabolism; Phosphocholine; Proto-Oncogene Proteins c-myc - metabolism; Science; Science (multidisciplinary); Serine; Signal transduction; Threonine; Transcription Factors - metabolism; tRNA Gly; tRNA Ser; Tumorigenesis
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-27375-z

Medulloblastoma (MB) is the most common malignant brain tumour in children. High-risk MB patients harbouring MYC  amplification or overexpression exhibit a very poor prognosis. Aberrant activation of MYC markedly reprograms cell metabolism to sustain tumorigenesis, yet how metabolism is dysregulated in MYC-driven MB is not well understood. Growing evidence unveiled the potential of BET-bromodomain inhibitors (BETis) as next generation agents for treating MYC-driven MB, but whether and how BETis may affect tumour cell metabolism to exert their anticancer activities remains unknown. In this study, we explore the metabolic features characterising MYC-driven MB and examine how these are altered by BET-bromodomain inhibition. To this end, we employed an NMR-based metabolomics approach applied to the MYC-driven MB D283 and D458 cell lines before and after the treatment with the BETi OTX-015. We found that OTX-015 triggers a metabolic shift in both cell lines resulting in increased levels of myo-inositol, glycerophosphocholine, UDP-N-acetylglucosamine, glycine, serine, pantothenate and phosphocholine. Moreover, we show that OTX-015 alters ascorbate and aldarate metabolism, inositol phosphate metabolism, phosphatidylinositol signalling system, glycerophospholipid metabolism, ether lipid metabolism, aminoacyl-tRNA biosynthesis, and glycine, serine and threonine metabolism pathways in both cell lines. These insights provide a metabolic characterisation of MYC-driven childhood MB cell lines, which could pave the way for the discovery of novel druggable pathways. Importantly, these findings will also contribute to understand the downstream effects of BETis on MYC-driven MB, potentially aiding the development of new therapeutic strategies to combat medulloblastoma.